Convivio 2024, a charity initiative dedicated to raising funds for HIV and infectious diseases, concluded its special edition with a magical fundraising dinner. Held at Fabbrica del Vapore in Milan, the event raised a record-breaking €1.8 million through a week-long shopping event and a dazzling gala dinner. The event featured unique table settings inspired by the theme of magic, showcasing the creativity and commitment of participating brands and sponsors.
A disturbing HIV outbreak in Ramnagar village, Uttarakhand, has been linked to a 17-year-old girl who, allegedly addicted to heroin, engaged in sexual relationships with multiple young men. The incident has raised concerns about the spread of the virus and highlights the urgent need for awareness, counseling, and support for vulnerable individuals.
Researchers have developed a new experimental HIV treatment, a single-dose, engineered virus that outcompetes HIV in the body. The treatment, tested in monkeys, dramatically suppressed HIV for at least seven months, suggesting long-lasting protection is possible. The next step is to test the treatment in humans.
A new HIV-preventive drug, lenacapavir, has demonstrated 100% efficacy and no safety concerns in a phase-3 trial involving young women in South Africa and Uganda. The twice-yearly injectable drug, developed by Gilead Sciences, Inc., showed zero HIV infections in the trial participants, compared to 39 and 16 infections in the groups receiving daily oral tablets Descovy and Truvada, respectively.
A groundbreaking HIV drug, Lenacapavir, could cost as little as $40 per year to manufacture, potentially revolutionizing the fight against the virus. Researchers estimate that the cost could be drastically reduced if generic versions are allowed, making the drug accessible to millions who currently cannot afford it.
A concerning HIV outbreak among students in Tripura has resulted in 47 deaths and 828 positive cases over the past 25 years. The Tripura State AIDS Control Society (TSACS) attributes the spread primarily to injectable drug use, particularly among students from affluent families. While the government acknowledges the issue, it emphasizes that many of the infected students are still alive and have migrated for further studies.
A groundbreaking clinical trial in Africa has shown that a new injectable drug, lenacapavir, offers complete protection against HIV infection among young women. The trial, conducted by Gilead Sciences, has yielded promising results, with zero cases of HIV infection reported among women who received the drug. This breakthrough offers hope for a significant shift in HIV prevention strategies, particularly in Africa where the burden of the disease is highest.
June 5th marks significant events in global health history. In 1981, the United States reported the first case of AIDS, a disease that has since become a major global health concern. In India, the year 1974 saw a devastating smallpox epidemic that claimed the lives of thousands. This article provides a brief overview of these historical events, highlighting their impact on public health and the ongoing efforts to combat infectious diseases.
Chronic kidney disease (CKD) is a serious condition that can affect people living with HIV. It is important to understand the risks, symptoms, and treatment options for CKD in order to prevent and manage the disease effectively. This article provides an overview of CKD in people with HIV, including information on screening, treatment, and the role of kidney transplantation.
Gilead Sciences, once written off as the “ugly duckling” of Big Pharma, has made significant strides in recent years. Its oncology portfolio is showing promise, its HIV treatments remain dominant, and it continues to generate solid cash flow. Despite these strengths, GILD stock has given back most of its gains since a late-2022 surge, creating a potential buying opportunity.
